Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 3Prostatic Neoplasms 1Prostatic Hyperplasia 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × TroVax × Clear all
NCT00083941 2020-10-19

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

Oxford BioMedica

Phase 2 Completed
25 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00325507 2020-10-19

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Oxford BioMedica

Phase 2 Completed
25 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00397345 2020-10-19

TroVax Renal Immunotherapy Survival Trial

Oxford BioMedica

Phase 3 Completed
733 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡